Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

NCT04942067 : A Phase Ib/II Open-Label Study of APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma and Immunoglobin Light Chain Amyloidosis

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

One/TwoPhase One/Two

18+Age Over 18

Blood<br/>CancersCancer LocationBlood
Cancers

Systemic therapy | Blood / Myeloma / LymphomaAmyloidosis,Multiple Myeloma

Trial Overview Read MoreRead more

This phase I/II trial is evaluating how safe, tolerable and effective a new targeted therapy (APG-2575) is when combined with other treatment regimens (Pd or DRd) in people with relapsed or refractory multiple myeloma and immunoglobin light chain amyloidosis.
 

This trial is treating patients with Relapsed or Refractory Multiple Myeloma and Immunoglobin Light Chain.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You are able to swallow medication by mouth.
  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
  • You have had treatment, but your cancer has come back.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase Ib/II Open-Label Study of APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma and Immunoglobin Light Chain Amyloidosis

Commercial Sponsor

Ascentage Pharma Group Inc.

Summary

This study has two arms, which are independent of each other, and each arm consists of dose escalation and dose expansion phases. In the dose escalation phase, APG-2575 will be administered at increasing doses until the recommended phase 2 dose (RP2D) is determined. In Arm 1, participants will receive APG-2575 in combination with Pomalidomide (4mg daily x 21 days) and dexamethasone (40mg for patients ≤ 75 years old or 20 mg for patients > 75 years old; on Days 1, 8, 15, and 22 of a repeated 28-day cycle). In Arm 2, participants will receive APG2575 in combination with Lenalidomide (25mg orally on Days 1-21 of each 28-day cycle), dexamethasone (40 mg [or 20 mg for patients > 75 years old] once weekly), and daratumumab (administered intravenously, 16mg/kg weekly in cycles 1 and 2 and then every 2 weeks in cycles 3-6 and every 4 weeks thereafter).

Recruiting Hospitals Read MoreRead more

Epworth Hospital Haematology
East Melbourne
Dr Connie Barlas
connie.barlas@epworth.org.au
03 9516 2374

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next